CN108458964A - A kind of antibody compositions and its application in the detection of lymphoma lymphoplasmacytic minimal residual - Google Patents
A kind of antibody compositions and its application in the detection of lymphoma lymphoplasmacytic minimal residual Download PDFInfo
- Publication number
- CN108458964A CN108458964A CN201711049005.3A CN201711049005A CN108458964A CN 108458964 A CN108458964 A CN 108458964A CN 201711049005 A CN201711049005 A CN 201711049005A CN 108458964 A CN108458964 A CN 108458964A
- Authority
- CN
- China
- Prior art keywords
- antibody
- compositions
- antibody compositions
- antibodies
- ssc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 206010025323 Lymphomas Diseases 0.000 title claims abstract description 13
- 238000001514 detection method Methods 0.000 title abstract description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 12
- 230000002159 abnormal effect Effects 0.000 claims abstract description 10
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 10
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000012360 testing method Methods 0.000 claims abstract description 6
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 239000002002 slurry Substances 0.000 claims abstract description 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 12
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 12
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 10
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 10
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims description 6
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims description 6
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 102000003729 Neprilysin Human genes 0.000 claims description 4
- 108090000028 Neprilysin Proteins 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims description 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims description 3
- -1 cKappa/cLambda Proteins 0.000 claims description 3
- 238000004458 analytical method Methods 0.000 abstract description 3
- 239000003550 marker Substances 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 238000011160 research Methods 0.000 abstract description 2
- 210000002798 bone marrow cell Anatomy 0.000 abstract 1
- 238000001914 filtration Methods 0.000 abstract 1
- OALHHIHQOFIMEF-UHFFFAOYSA-N 3',6'-dihydroxy-2',4',5',7'-tetraiodo-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(I)=C(O)C(I)=C1OC1=C(I)C(O)=C(I)C=C21 OALHHIHQOFIMEF-UHFFFAOYSA-N 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 3
- 210000002751 lymph Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004180 plasmocyte Anatomy 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 206010062489 Leukaemia recurrent Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
- G01N15/10—Investigating individual particles
- G01N15/14—Optical investigation techniques, e.g. flow cytometry
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Peptides Or Proteins (AREA)
Abstract
A kind of application the present invention provides antibody compositions and its in the detection of lymphoma lymphoplasmacytic minimal residual, the technical solution combines clinical practice for many years and research, the antibody compositions for filtering out two Guan Base totally 16 antibody, can be efficient, sensitively distinguishes and identifies abnormal cell group.On this basis, preferred FITC, PE, Percp5.5, Pe cy7, APC, AF750, BV421, V500 fluorescent marker for being used for antibody of the present invention realizes and detects a streaming pipe in the eight color flow cytometer single tubes and obtain 8 kinds of Antibody Results.At the same time, the present invention is based on the corresponding analysis methods that 45/SSC joint gatings devise testing result, and to judge that thick liquid cell, bone-marrow-derived lymphocyte are Clonal, and whether abnormal slurry sample lymphocyte is detected.The antibody compositions of the present invention can be directly used for carrying out the MRD detections of LPL, it can also be used to the preparation of related kit.
Description
Technical field
The present invention relates to biological experiment technical fields, and in particular to a kind of antibody compositions and its in lympho-plasmacytic
Application in the detection of lymthoma minimal residual.
Background technology
Lymphoma lymphoplasmacytic (LPL) be it is a kind of by abnormal small bone-marrow-derived lymphocyte, abnormal plasmocyte sample lymphocyte and
The tumour of abnormal plasmocyte composition, usually involves marrow, lymph node and spleen.Leukaemia microscopic residue (MRD) refers in white blood
Disease still remains the state of a small amount of leukaemia cell in vivo after induction chemother obtains complete incidence graph or after bone marrow transplantation therapy.
At this point, being difficult to detect the presence of leukaemia cell, but the leukaemia actually in Bone Marrow of Patients with the method for gross morphology
There is also the cell of these remainings becomes the root of leukemia relapse to cell.
In hemopathic diagnosis and treatment process, when disease has been made a definite diagnosis, after implementing treatment or even alleviating, it is still desirable to detect micro-
Small residual, MRD values are related to the size of clinical medicine dose.There are many antibody in terms of disease parting at present for flow cyctometry
Combination, but there is leakage in checkout and diagnosis MRD in the antibody combination for not being directed to the MRD detections of LPL in the prior art
The possibility examined can be delayed patient's therapic opportunity.
Invention content
The present invention is directed to the technological deficiency for the prior art, a kind of antibody compositions are provided and its in lympho-plasmacytic
It is small to lack a kind of detection lymphoma lymphoplasmacytic in the prior art with solution for application in the detection of lymthoma minimal residual
The technical issues of method of residue.
Another technical problem to be solved by the present invention is that lacking in the prior art a kind of for Flow cytometry lymph
The antibody compositions of plasmacytic lymphoma microscopic residue and clinical analysis method around testing result.
To realize that the above technical purpose, the present invention use following technical scheme：
A kind of antibody compositions, including anti-cLambda antibody (endochylema Lambda), anti-CD138 antibody, anti-CD56 antibody,
Anti- CD117 antibody, anti-cKappa antibody (endochylema Kappa), anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody.
Preferably, the antibody compositions are by anti-cLambda antibody (endochylema Lambda), anti-CD138 antibody, anti-CD56 is anti-
Body, anti-CD117 antibody, anti-cKappa antibody (endochylema Kappa), anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody composition.
Preferably, above each antibody is marked as different fluoresceins, wherein the different fluorescein is respectively：
FITC, PE, Percp5.5, Pe-cy7, APC, AF750, BV421, V500.
A kind of antibody compositions, including anti-Lambda antibody (after birth Lambda), anti-CD10 antibody, anti-CD5 antibody resist
CD20 antibody, anti-Kappa antibody (after birth Kappa), anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody.
Preferably, the antibody compositions are by anti-Lambda antibody (after birth Lambda), and anti-CD10 antibody, anti-CD5 antibody,
Anti-CD 20 antibodies, anti-Kappa antibody (after birth Kappa), anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody composition.
Preferably, above each antibody is marked as different fluoresceins, wherein the different fluorescein is respectively：
FITC, PE, Percp5.5, Pe-cy7, APC, AF750, BV421, V500.
Preferably, antibody described above is monoclonal antibody；The source behaviour source of the antibody or mouse source.
A kind of kit for detecting lymphoma lymphoplasmacytic microscopic residue comprising the first container and second
Container, wherein the first container includes the antibody compositions of the above first aspect；The second container includes the above second party
The antibody compositions in face.
More than one described antibody compositions are used for small residual by Flow cytometry lymphoma lymphoplasmacytic
Stay the application of object.
Preferably, being analyzed by continuous gating method testing result in this application, wherein the first pipe is FSC/
SSC, CD45/SSC, CD138/CD38, CD45/CD19, cKappa/cLambda, CD19/CD56；Second pipe be FSC/SSC,
CD45/SSC、CD19/CD20、CD10//CD5、Kappa/Lambda、CD19/CD38；Thick liquid cell and B lymphs are then judged respectively
Whether cell clonal, and abnormal slurry sample lymphocyte are detected.
Answering the present invention provides a kind of antibody compositions and its in the detection of lymphoma lymphoplasmacytic minimal residual
Clinical practice for many years and research are combined with, the technical solution, filters out the antibody compositions of two Guan Base totally 16 antibody, it can
With efficient, sensitively distinguish and identify abnormal cell group.On this basis, the preferred FITC, PE for antibody of the present invention,
Percp5.5, Pe-cy7, APC, AF750, BV421, V500 fluorescent marker are realized and are detected in eight color flow cytometer single tubes
A piece streaming pipe obtains whole Antibody Results.At the same time, the present invention is based on 45/SSC joint gatings to devise testing result
Corresponding analysis method, to judge that thick liquid cell and bone-marrow-derived lymphocyte are Clonal, and whether abnormal slurry sample lymphocyte is detected
Go out.The antibody compositions of the present invention can be directly used for carrying out the MRD detections of LPL, it can also be used to the preparation of related kit.
Specific implementation mode
The specific implementation mode of the present invention will be described in detail below.In order to avoid excessive unnecessary details,
It will not be described in detail in following embodiment to belonging to well known structure or function.Approximation used in following embodiment
Language can be used for quantitative expression, show to allow quantity to have certain variation in the case where not changing basic function.It is fixed except having
Adopted outer, technical and scientific term used in following embodiment has the phase being commonly understood by with those skilled in the art of the invention
Same meaning.
Embodiment 1
A kind of antibody compositions, by anti-cLambda antibody, anti-CD138 antibody, anti-CD56 antibody, anti-CD117 antibody, resist
CKappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody composition.
Another antibody compositions, by anti-Lambda antibody, anti-CD10 antibody, anti-CD5 antibody, anti-CD 20 antibodies, resist
Kappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody composition.
Above each antibody is marked as different fluoresceins, wherein the different fluorescein is respectively：FITC, PE,
Percp5.5, Pe-cy7, APC, AF750, BV421, V500.
The antibody is monoclonal antibody；The source behaviour source of the antibody or mouse source.
A kind of kit for detecting lymphoma lymphoplasmacytic microscopic residue comprising the first container and second
Container, wherein the first container includes the first above antibody compositions；The second container includes above second of the antibody
Composition.
Any of the above item antibody compositions are used for small by Flow cytometry lymphoma lymphoplasmacytic
The application of residue.
On the basis of the application, testing result is analyzed by continuous gating method, wherein the first pipe is FSC/
SSC, CD45/SSC, CD138/CD38, CD45/CD19, cKappa/cLambda, CD19/CD56；Second pipe be FSC/SSC,
CD45/SSC、CD19/CD20、CD10//CD5、Kappa/Lambda、CD19/CD38；Thick liquid cell and B lymphs are then judged respectively
Whether cell clonal, and abnormal slurry sample lymphocyte are detected.
Embodiment 2
A kind of antibody compositions, including anti-cLambda antibody, anti-CD138 antibody, anti-CD56 antibody, anti-CD117 antibody,
Anti- cKappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody.
Above each antibody is marked as different fluoresceins, wherein the different fluorescein is respectively：FITC, PE,
Percp5.5, Pe-cy7, APC, AF750, BV421, V500.
Another antibody compositions, by anti-Lambda antibody, anti-CD10 antibody, anti-CD5 antibody, anti-CD 20 antibodies, resist
Kappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody composition.
A kind of kit for detecting lymphoma lymphoplasmacytic microscopic residue comprising the first container and second
Container, wherein the first container includes the first above antibody compositions；The second container includes above second of the antibody
Composition.
Any one of more than one antibody compositions are used to pass through Flow cytometry lymphoma lymphoplasmacytic
The application of microscopic residue.
Embodiment 3
A kind of antibody compositions, including anti-cLambda antibody, anti-CD138 antibody, anti-CD56 antibody, anti-CD117 antibody,
Anti- cKappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody.
Another antibody compositions, including anti-Lambda antibody, anti-CD10 antibody, anti-CD5 antibody, anti-CD 20 antibodies resist
Kappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody.
The embodiments of the present invention have been described in detail above, but content is only the preferred embodiment of the present invention,
It is not intended to limit the invention.All all any modification, equivalent and improvement etc. done in the application range of the present invention, should all
It is included within protection scope of the present invention.
Claims (10)
1. a kind of antibody compositions, including anti-cLambda antibody, anti-CD138 antibody, anti-CD56 antibody, anti-CD117 antibody resist
CKappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody.
2. a kind of antibody compositions according to claim 1, it is characterised in that the antibody compositions are resisted by anti-cLambda
Body, anti-CD138 antibody, anti-CD56 antibody, anti-CD117 antibody, anti-cKappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb resist
CD45 antibody forms.
3. a kind of antibody compositions according to claim 1 or 2, it is characterised in that each antibody is marked as different fluorescence
Element, wherein the different fluorescein is respectively：FITC, PE, Percp5.5, Pe-cy7, APC, AF750, BV421, V500.
4. a kind of antibody compositions, including anti-Lambda antibody, anti-CD10 antibody, anti-CD5 antibody, anti-CD 20 antibodies, anti-Kappa
Antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody.
5. a kind of antibody compositions according to claim 4, it is characterised in that the antibody compositions by anti-Lambda antibody,
Anti- CD10 antibody, anti-CD5 antibody, anti-CD 20 antibodies, anti-Kappa antibody, anti-CD 19 antibodies, 8 antibody of AntiCD3 McAb, anti-CD45 antibody
Composition.
6. a kind of antibody compositions according to claim 4 or 5, it is characterised in that each antibody is marked as different fluorescence
Element, wherein the different fluorescein is respectively：FITC, PE, Percp5.5, Pe-cy7, APC, AF750, BV421, V500.
7. according to a kind of 1,2,4,5 antibody compositions of any one of them of claim, it is characterised in that the antibody is Dan Ke
Grand antibody；The source behaviour source of the antibody or mouse source.
8. a kind of kit for detecting lymphoma lymphoplasmacytic microscopic residue comprising the first container and second is held
Device, wherein the first container includes antibody compositions as claimed in claim 1 or 2；The second container includes claim 4
Or the antibody compositions described in 5.
9. a kind of 1,2,4,5 any one antibody compositions of claim are used to pass through Flow cytometry lymphoplasmacytic
The application of property lymthoma microscopic residue.
10. application according to claim 9, it is characterised in that testing result is analyzed by continuous gating method,
In first pipe be FSC/SSC, CD45/SSC, CD138/CD38, CD45/CD19, cKappa/cLambda, CD19/CD56；Second
Pipe is FSC/SSC, CD45/SSC, CD19/CD20, CD10//CD5, Kappa/Lambda, CD19/CD38；Then judge respectively
Thick liquid cell and bone-marrow-derived lymphocyte are Clonal, and whether abnormal slurry sample lymphocyte is detected.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711049005.3A CN108458964A (en) | 2017-10-31 | 2017-10-31 | A kind of antibody compositions and its application in the detection of lymphoma lymphoplasmacytic minimal residual |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711049005.3A CN108458964A (en) | 2017-10-31 | 2017-10-31 | A kind of antibody compositions and its application in the detection of lymphoma lymphoplasmacytic minimal residual |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108458964A true CN108458964A (en) | 2018-08-28 |
Family
ID=63221167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711049005.3A Pending CN108458964A (en) | 2017-10-31 | 2017-10-31 | A kind of antibody compositions and its application in the detection of lymphoma lymphoplasmacytic minimal residual |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108458964A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109655616A (en) * | 2018-12-19 | 2019-04-19 | 广州金域医学检验中心有限公司 | Detect the composite reagent and system of acute myeloid leukemia cell |
| CN112578117A (en) * | 2021-02-22 | 2021-03-30 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | Antibody composition and application thereof in screening post-transplantation lymphocyte proliferative diseases |
| CN113049815A (en) * | 2019-12-26 | 2021-06-29 | 上海益诺思生物技术股份有限公司 | Flow type gate-circling method for cynomolgus monkey lymphocytes |
| CN113777327A (en) * | 2021-09-13 | 2021-12-10 | 北京大学人民医院 | Antibody composition for leukemia/lymphoma immunophenotyping primary screening and application thereof |
| CN113933513A (en) * | 2021-12-15 | 2022-01-14 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | Reagent composition for detecting acute T lymphocyte leukemia after targeted therapy and application thereof |
| CN115197322A (en) * | 2022-07-21 | 2022-10-18 | 江苏省人民医院（南京医科大学第一附属医院） | Antibody composition for detecting minimal residual disease of chronic lymphocytic leukemia and application thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004102198A3 (en) * | 2003-05-15 | 2005-01-27 | Cytos Biotechnology Ag | Selection of b cells with specificity of interest: method of preparation and use |
| CN101946171A (en) * | 2007-12-14 | 2011-01-12 | 拜奥蒂乌姆股份有限公司 | Fluorescent compounds |
| CN104471393A (en) * | 2012-06-14 | 2015-03-25 | 鹿特丹伊拉斯姆斯大学医疗中心 | Methods, reagents and kits for detecting minimal residual disease |
| CN105051521A (en) * | 2013-03-15 | 2015-11-11 | 贝克曼考尔特公司 | Systems and methods for panel design in flow cytometry |
| CN105223360A (en) * | 2015-08-28 | 2016-01-06 | 北京大学人民医院 | Differentiate to detect normal plasma cells and Clonal plasmacytic kit and application thereof |
| CN105606797A (en) * | 2016-01-15 | 2016-05-25 | 浙江博真生物科技有限公司 | Antibody composition and application of antibody composition in leukemia and lymphoma typing |
| CN106290812A (en) * | 2016-09-08 | 2017-01-04 | 北京海思特临床检验所有限公司 | B cell malignant tumor related antigen expression amount detection kit and detection method |
| CN106771205A (en) * | 2017-01-18 | 2017-05-31 | 浙江博真生物科技有限公司 | Ten color antibody compositions and its application in leukemia-lymphoma parting |
| CN107074951A (en) * | 2014-08-04 | 2017-08-18 | 贝勒研究院 | Antagonism anti-OX 40 l antibodies and its application method |
| CN107209187A (en) * | 2014-07-11 | 2017-09-26 | 国立健康与医学研究所 | Method for diagnosing hematologic cancers |
-
2017
- 2017-10-31 CN CN201711049005.3A patent/CN108458964A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004102198A3 (en) * | 2003-05-15 | 2005-01-27 | Cytos Biotechnology Ag | Selection of b cells with specificity of interest: method of preparation and use |
| CN101946171A (en) * | 2007-12-14 | 2011-01-12 | 拜奥蒂乌姆股份有限公司 | Fluorescent compounds |
| CN104471393A (en) * | 2012-06-14 | 2015-03-25 | 鹿特丹伊拉斯姆斯大学医疗中心 | Methods, reagents and kits for detecting minimal residual disease |
| CN105051521A (en) * | 2013-03-15 | 2015-11-11 | 贝克曼考尔特公司 | Systems and methods for panel design in flow cytometry |
| CN107209187A (en) * | 2014-07-11 | 2017-09-26 | 国立健康与医学研究所 | Method for diagnosing hematologic cancers |
| CN107074951A (en) * | 2014-08-04 | 2017-08-18 | 贝勒研究院 | Antagonism anti-OX 40 l antibodies and its application method |
| CN105223360A (en) * | 2015-08-28 | 2016-01-06 | 北京大学人民医院 | Differentiate to detect normal plasma cells and Clonal plasmacytic kit and application thereof |
| CN105606797A (en) * | 2016-01-15 | 2016-05-25 | 浙江博真生物科技有限公司 | Antibody composition and application of antibody composition in leukemia and lymphoma typing |
| CN106290812A (en) * | 2016-09-08 | 2017-01-04 | 北京海思特临床检验所有限公司 | B cell malignant tumor related antigen expression amount detection kit and detection method |
| CN106771205A (en) * | 2017-01-18 | 2017-05-31 | 浙江博真生物科技有限公司 | Ten color antibody compositions and its application in leukemia-lymphoma parting |
Non-Patent Citations (2)
| Title |
|---|
| 管忠霞: "《儿童淋巴瘤诊断与治疗》", 30 August 2016, 广东科技出版社 * |
| 许艳丽等: "多参数流式细胞术在多发性骨髓瘤及其微小残留疾病的免疫表型分析", 《国际检验医学杂志》 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109655616A (en) * | 2018-12-19 | 2019-04-19 | 广州金域医学检验中心有限公司 | Detect the composite reagent and system of acute myeloid leukemia cell |
| CN109655616B (en) * | 2018-12-19 | 2022-05-06 | 广州金域医学检验中心有限公司 | Combined reagent and system for detecting acute myeloid leukemia cells |
| CN113049815A (en) * | 2019-12-26 | 2021-06-29 | 上海益诺思生物技术股份有限公司 | Flow type gate-circling method for cynomolgus monkey lymphocytes |
| CN112578117A (en) * | 2021-02-22 | 2021-03-30 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | Antibody composition and application thereof in screening post-transplantation lymphocyte proliferative diseases |
| CN112578117B (en) * | 2021-02-22 | 2021-05-25 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | Antibody composition and application thereof in screening post-transplantation lymphocyte proliferative diseases |
| CN113777327A (en) * | 2021-09-13 | 2021-12-10 | 北京大学人民医院 | Antibody composition for leukemia/lymphoma immunophenotyping primary screening and application thereof |
| CN113933513A (en) * | 2021-12-15 | 2022-01-14 | 信纳克(北京)生化标志物检测医学研究有限责任公司 | Reagent composition for detecting acute T lymphocyte leukemia after targeted therapy and application thereof |
| CN115197322A (en) * | 2022-07-21 | 2022-10-18 | 江苏省人民医院（南京医科大学第一附属医院） | Antibody composition for detecting minimal residual disease of chronic lymphocytic leukemia and application thereof |
| CN115197322B (en) * | 2022-07-21 | 2024-01-30 | 江苏省人民医院（南京医科大学第一附属医院） | Antibody composition for detecting micro residual focus of chronic lymphocytic leukemia and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108458964A (en) | A kind of antibody compositions and its application in the detection of lymphoma lymphoplasmacytic minimal residual | |
| Belov et al. | Identification of repertoires of surface antigens on leukemias using an antibody microarray | |
| Garnache‐Ottou et al. | Extended diagnostic criteria for plasmacytoid dendritic cell leukaemia | |
| Guo et al. | Detection of BCR-ABL proteins in blood cells of benign phase chronic myelogenous leukemia patients | |
| CN106635995A (en) | Circulating tumor cell negative enrichment method | |
| CN112552407B (en) | Antibody composition and application thereof in detecting acute B lymphocyte leukemia | |
| Kim et al. | A microchip filter device incorporating slit arrays and 3-D flow for detection of circulating tumor cells using CAV1-EpCAM conjugated microbeads | |
| Demurtas et al. | Usefulness of multiparametric flow cytometry in detecting composite lymphoma: study of 17 cases in a 12-year period | |
| Cherian et al. | Common flow cytometry pitfalls in diagnostic hematopathology | |
| WO2018214623A1 (en) | Microfluidic chip for circulating tumor cell separation, circulating tumor cell separation method and counting method | |
| Donaubauer et al. | Analysis of the immune status from peripheral whole blood with a single-tube multicolor flow cytometry assay | |
| CN105223360B (en) | Kit for detection and identification of normal plasma cell and clonal plasma cell and application thereof | |
| Gunduz et al. | Peripheral blood regulatory T cell levels are correlated with some poor prognostic markers in newly diagnosed lymphoma patients | |
| Yu et al. | Individualized leukemia cell-population profiles in common B-cell acute lymphoblastic leukemia patients | |
| Kim et al. | Prediction of tumor metastasis via extracellular vesicles-treated platelet adhesion on a blood vessel chip | |
| CN110272487A (en) | A kind of pipette tips formula dispersed solid phase microextraction column, the purification process based on the pipette tips formula dispersed solid phase microextraction column and application | |
| van der Haar Àvila et al. | Evaluating antibody-dependent cell-mediated cytotoxicity by flow cytometry | |
| Garcia et al. | Semi-automatic pd-l1 characterization and enumeration of circulating tumor cells from non-small cell lung cancer patients by immunofluorescence | |
| CN206431143U (en) | A kind of portable clenbuterol hydrochloride detection kit | |
| CN108548920A (en) | A kind of detection method for the kit detecting circulating tumor cell using immunomagnetic beads negative sense absorption joint flow cytometry | |
| Bradstock et al. | Myeloid progenitor surface antigen identified by monoclonal antibody | |
| Li et al. | Delayed diagnosis of Angioimmunoblast T-cell lymphoma presenting with type II Cryoglobulinemia and acute kidney injury: a case report and narrative review of the literature | |
| Krause et al. | Flow cytometry for hematopoietic cells | |
| Liang et al. | Treatment of plasmablastic lymphoma with multiple organ involvement | |
| Carulli et al. | Morphologic and immunophenotypic features of a case of acute monoblastic leukemia with unusual positivity for Glycophorin-A |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180828 |